Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Aprepitant, sold under the brand name Emend among others, is a medication used to prevent chemotherapy-induced nausea and vomiting and to prevent postoperative nausea and vomiting. It may be used together with ondansetron and dexamethasone. It is taken by mouth or administered by intravenous injection. A prodrug, fosaprepitant, is also available for…
History & Research
Explore the main themes, entities and connections around Aprepitant. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
vomiting nk1 process used nausea synthesis receptor also ondansetron step substance receptors merck side effects use cyp3a4 drug antagonist administration
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Aprepitant | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Aprepitant | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Aprepitant | ATC code | A04AD12 (WHO) | 1.00 | infobox |
| Aprepitant | Bioavailability | 60–65% | 1.00 | infobox |
| Aprepitant | CAS Number | 170729-80-3 Y | 1.00 | infobox |
| Aprepitant | ChEBI | CHEBI:499361 Y | 1.00 | infobox |
| Aprepitant | ChEMBL | ChEMBL1471 Y | 1.00 | infobox |
| Aprepitant | ChemSpider | 5293568 Y | 1.00 | infobox |
| Aprepitant | CompTox Dashboard (EPA) | DTXSID3049047 | 1.00 | infobox |
| Aprepitant | Drug class | NK1 receptor antagonist, antiemetic | 1.00 | infobox |
| Aprepitant | DrugBank | DB00673 Y | 1.00 | infobox |
| Aprepitant | ECHA InfoCard | 100.202.762 | 1.00 | infobox |
| Aprepitant | Elimination half-life | 9–13 hours | 1.00 | infobox |
| Aprepitant | Excretion | Kidney (57%), feces (45%) | 1.00 | infobox |
| Aprepitant | Formula | C23H21F7N4O3 | 1.00 | infobox |
| Aprepitant | IUPHAR/BPS | 3490 | 1.00 | infobox |
| Aprepitant | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Aprepitant | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Aprepitant | Legal status | US: ℞-only | 1.00 | infobox |
| Aprepitant | Legal status | EU: Rx-only | 1.00 | infobox |
| Aprepitant | License data | US DailyMed: Aprepitant | 1.00 | infobox |
| Aprepitant | MedlinePlus | a604003 | 1.00 | infobox |
| Aprepitant | Metabolism | Liver (mostly CYP3A4- mediated; some contributions by CYP2C19 & CYP1A2) | 1.00 | infobox |
| Aprepitant | Molar mass | 534.435 g·mol−1 | 1.00 | infobox |
| Aprepitant | Pregnancy category | AU: B1 | 1.00 | infobox |
| Aprepitant | Protein binding | >95% | 1.00 | infobox |
| Aprepitant | PubChem CID | 6918365 | 1.00 | infobox |
| Aprepitant | Routes of administration | By mouth | 1.00 | infobox |
| Aprepitant | Trade names | Emend, Cinvanti, Aponvie, others | 1.00 | infobox |
| Aprepitant | UNII | 1NF15YR6UY | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.